All Axovant Sciences articles
-
Business
Gene therapy gathers pace
Sarah Houlton charts the evolution, challenges and opportunities of cell and gene therapy
-
Business
Dementia slips down pharma agenda
Pfizer, Shire, Acorda and Axovant rethink their neuroscience strategies